vaccine – Page 4 – media

MIT’s new injection tech delivers multiple vaccines with one poke

Regardless of what it’s protecting you against, few people would likely say that getting a vaccine injection is an altogether enjoyable vaccine. Fortunately, engineers at the Massachusetts Institute of Technology are coming to the rescue with a new 3D fabrication technique that could allow for multiple doses of a drug or vaccine to be delivered to a patient over an extended period of time — with just one jab needed.
- Source: digitaltrends
- 746
- September 25, 2017
Company Insight fabrication needle-phobic vaccine
GlaxoSmithKline taking heat in its U.K. home turf over shortages of hepatitis B vaccine

GlaxoSmithKline is taking some heat at home over questions about global shortages of its and Merck’s hepatitis B vaccine that triggered rationing in the U.K., although GSK’s supplies to the much larger U.S. market seem to be unaffected.
- Source: fiercepharma
- 596
- August 24, 2017
hepatitis Market Views vaccine
New flu vaccine approved for UK use

The adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older has been cleared by the Medicines and Healthcare products Regulatory Agency.
- Source: pharmatimes
- 684
- August 23, 2017
influenza New Approvals trivalent vaccine
GSK opens new aluminium salts facility in Scotland

Being set to supply ingredients for around 400 million vaccines a year, a new £44 million aluminium salts facilityhas been officially opened by GlaxoSmithKline in Montrose, Scotland.
- Source: news.open-medical
- 637
- August 17, 2017
aluminium salt Company Insight HIV ingredient respiratory vaccine
FDA extends review on Dynavax’s Heplisav-B

FDA extends review on Dynavax's hepatitis B vaccine candidate Heplisav-B, but both management and analysts said they remain confident in approval.
- Source: fiercepharm
- 632
- August 7, 2017
Company Insight FDA hepatitis Heplisav-B Market Views vaccine
Sanofi snaps up Protein Sciences for $650 million

Sanofi is to buy private US vaccines biotech Protein Sciences in a deal valued at up to $750 million, in a move to bolster its vaccines portfolio.
- Source: pharmatimes
- 466
- July 7, 2017
Company Insight Market Views vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.